| scholarly article | Q13442814 |
| P2093 | author name string | Richter A | |
| Fransson SG | |||
| Lindahl TL | |||
| Järemo P | |||
| P2860 | cites work | Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration | Q29619529 |
| Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study | Q33333456 | ||
| Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population | Q33338347 | ||
| Inverse relationship between platelet density and reactivity alterations at coronary angiography. | Q43642140 | ||
| Effect of 300- and 450-mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation | Q43843821 | ||
| Prevention of Activated Neutrophil Adhesion to Endothelium by Soluble Adhesion Protein GMP140 | Q46852557 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | clopidogrel | Q410237 |
| P1104 | number of pages | 6 | |
| P304 | page(s) | 233-238 | |
| P577 | publication date | 2002-09-01 | |
| P1433 | published in | Journal of Internal Medicine | Q6295387 |
| P1476 | title | Individual variations of platelet inhibition after loading doses of clopidogrel | |
| P478 | volume | 252 |
| Q84587501 | A comparison of INNOVANCE® PFA P2Y and VerifyNow P2Y12 assay for the assessment of clopidogrel resistance in patients undergoing percutaneous coronary intervention |
| Q41868121 | A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans |
| Q46626905 | A new self-expandable nitinol stent for the treatment of wide-neck aneurysms: initial clinical experience |
| Q46934463 | A novel fifteen minute test for assessment of individual time-dependent clotting responses to aspirin and clopidogrel using modified thrombelastography |
| Q46244126 | A paradigm shift in anti-platelet therapy? |
| Q40329955 | A point-of-care assay to measure platelet aggregation in patients taking clopidogrel |
| Q40014803 | Antiplatelet Resistance-Does it Exist and How to Measure it? |
| Q37437158 | Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements |
| Q37443855 | Antiplatelet drug 'resistance'. Part 2: laboratory resistance to antiplatelet drugs-fact or artifact? |
| Q28201011 | Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4 |
| Q28199136 | Antiplatelet resistance with aspirin and clopidogrel: is it real and does it matter? |
| Q64088195 | Aspirin and Clopidogrel Resistance in Indian Patients with Ischemic Stroke and its Associations with Gene Polymorphisms: A Pilot Study |
| Q28194021 | Aspirin and clopidogrel resistance: an emerging clinical entity |
| Q28200610 | Aspirin and clopidogrel resistance: consideration and management |
| Q38132923 | Assessing post-treatment platelet reactivity: a focus on patient selection and setting. |
| Q53584028 | Association of CYP2C19, CYP3A5 and GPIIb/IIIa gene polymorphisms with Aspirin and Clopidogrel Resistance in a cohort of Indian patients with Coronary Artery Disease. |
| Q37683552 | Balancing the benefits and risks of antiplatelet agents in patients with non-ST-segment elevated acute coronary syndromes and undergoing percutaneous coronary intervention |
| Q38059154 | Biomarkers in acute coronary artery disease |
| Q42542451 | Cangrelor increases the magnitude of platelet inhibition and reduces interindividual variability in clopidogrel-pretreated subjects |
| Q41874943 | Cigarette smoking might weaken the prognostic significance of cytochrome P450 2C19*2 polymorphism in acute myocardial infarction patients |
| Q38059616 | Clinical impact of genetically determined platelet reactivity |
| Q50676873 | Clopidogrel anti-platelet effect: an evaluation by optical aggregometry, impedance aggregometry, and the platelet function analyzer (PFA-100). |
| Q28176741 | Clopidogrel in acute coronary syndrome: when, how much, how long? |
| Q44299095 | Clopidogrel resistance is associated with thromboembolic complications in patients undergoing neurovascular stenting |
| Q40347840 | Clopidogrel resistance: fact and fiction |
| Q37924998 | Clopidogrel resistance: identifying and overcoming a barrier to effective antiplatelet treatment |
| Q28218055 | Clopidogrel resistance: myth or reality? |
| Q44628707 | Complete lysis of left ventricular giant thrombus with fibrinolytic therapy in clopidogrel resistant patient |
| Q35176276 | Cytochrome P450 2C19 polymorphism is associated with reduced clopidogrel response in cerebrovascular disease |
| Q35683705 | Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome |
| Q28187591 | Determinants of the interindividual variability in response to antiplatelet drugs |
| Q37167506 | Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularization |
| Q37752222 | Dosing strategies for antiplatelet therapy in percutaneous coronary intervention. |
| Q36979338 | Drug evaluation of clopidogrel in patients with ischemic stroke |
| Q28198683 | Drug insight: Clopidogrel nonresponsiveness |
| Q38198567 | Dyspnea and reversibility profile of P2Y₁₂ antagonists: systematic review of new antiplatelet drugs. |
| Q38694069 | Effects of P2Y12 receptor antagonists beyond platelet inhibition--comparison of ticagrelor with thienopyridines |
| Q34352152 | Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease |
| Q28219204 | Evaluation of the TEG platelet mapping assay in blood donors |
| Q35583183 | Findings of intravascular ultrasound during acute stent thrombosis. |
| Q45213002 | Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases |
| Q38396605 | Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis |
| Q88842612 | Genetic Determinants of P2Y12 Inhibitors and Clinical Implications |
| Q38262149 | Genotype- and phenotype-directed antiplatelet therapy selection in patients with acute coronary syndromes |
| Q30450312 | High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study |
| Q28194081 | High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome |
| Q34536091 | Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism |
| Q28221442 | Hypercoagulability and platelet inhibition after OPCAB. Randomized intervention with clopidogrel |
| Q36216896 | Impact of CYP2C19 Variants on Clinical Efficacy of Clopidogrel and 1-Year Clinical Outcomes in Coronary Heart Patients Undergoing Percutaneous Coronary Intervention |
| Q38154612 | Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease: an historical account |
| Q34568130 | Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel |
| Q56525434 | Individual long-term variation of platelet reactivity in patients with dual antiplatelet therapy after myocardial infarction |
| Q42952510 | Intra-individual variability in clopidogrel responsiveness in coronary artery disease patients under long term therapy |
| Q47279466 | Inverse relationship between erythrocyte size and platelet reactivity in elderly |
| Q46596632 | Inverse relationships between coronary blood flow obstruction and platelet reactivity in stable angina pectoris. |
| Q37164391 | Investigating the mechanisms of hyporesponse to antiplatelet approaches |
| Q38012079 | Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention |
| Q50979186 | Low-density platelet populations demonstrate low in vivo activity in sporadic Alzheimer disease. |
| Q51480363 | Measurement of platelet aggregation functions using whole blood migration ratio in a microfluidic chip. |
| Q58841190 | Medium on-treatment platelet reactivity to ADP is favorable in patients with acute coronary syndromes undergoing coronary stenting |
| Q40000465 | Mild hypothermia does not attenuate platelet aggregation and may even increase ADP-stimulated platelet aggregation after clopidogrel treatment |
| Q46789035 | Monitoring of clopidogrel-related platelet inhibition: correlation of nonresponse with clinical outcome in supra-aortic stenting |
| Q46523098 | New antiplatelet therapies in development |
| Q38366950 | Novel anti-platelet agents in acute coronary syndrome: mechanisms of action and opportunities to tailor therapy. |
| Q41571629 | Oral antiplatelet therapy and platelet inhibition: An experience from a tertiary care center |
| Q35141555 | Overcoming aspirin resistance with loading clopidogrel earlier in elective percutaneous coronary intervention. |
| Q26745619 | P2Y12-ADP receptor antagonists: Days of future and past |
| Q37642822 | Personalized antiplatelet therapy for coronary artery disease patients: is this the future? |
| Q37877165 | Personalized antiplatelet therapy: review of the latest clinical evidence |
| Q28195019 | Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin |
| Q38101963 | Pharmacotherapy for the reduction of stent thrombosis |
| Q40586807 | Platelet Activation and Clopidogrel Effects on ADP-Induced Platelet Activation in Cats with or without the A31P Mutation in MYBPC3. |
| Q88805566 | Platelet Function Analyzer-200 P2Y Results Are Predictive of the Risk of Major Adverse Cardiac Events in Korean Patients Receiving Clopidogrel Therapy Following Acute Coronary Syndrome |
| Q34035039 | Platelet function monitoring in patients on clopidogrel: What should we learn from GRAVITAS? |
| Q44479790 | Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target |
| Q35957147 | Platelets, gender and acute cerebral infarction. |
| Q43077737 | Point-of-care platelet function assays demonstrate reduced responsiveness to clopidogrel, but not aspirin, in patients with Drug-Eluting Stent Thrombosis whilst on dual antiplatelet therapy |
| Q41349792 | Point-of-care platelet function testing in patients undergoing PCI: between a rock and a hard place |
| Q44426942 | Poor agreement between light transmission aggregometry, Verify Now P2Y₁₂ and vasodilatator-stimulated phosphoprotein for clopidogrel low-response assessment: a potential explanation of negative results of recent randomized trials. |
| Q41742863 | Post receptor determinants of acute platelet response to clopidogrel in patients with symptomatic myocardial ischemia. |
| Q36174036 | Residual platelet ADP reactivity after clopidogrel treatment is dependent on activation of both the unblocked P2Y(1) and the P2Y (12) receptor and is correlated with protein expression of P2Y (12) |
| Q37268748 | Resistance to Clopidogrel among Iranian Patients Undergoing Angioplasty Intervention |
| Q28192298 | Resistance to antiplatelet drugs: current status and future research |
| Q28182158 | Resistance to antiplatelet therapy |
| Q34990721 | Routine screening for CYP2C19 polymorphisms for patients being treated with clopidogrel is not recommended |
| Q37234897 | Static platelet adhesion, flow cytometry and serum TXB2 levels for monitoring platelet inhibiting treatment with ASA and clopidogrel in coronary artery disease: a randomised cross-over study |
| Q28196159 | Suspected clopidogrel resistance in a patient with acute stent thrombosis |
| Q46057801 | The P2Y12 receptor: no active metabolite, no party |
| Q39249688 | The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics |
| Q26801867 | The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19 |
| Q46566202 | The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies. |
| Q36664802 | Thrombelastography: current clinical applications and its potential role in interventional cardiology |
| Q28200486 | Thromboelastography: potential bedside tool to assess the effects of antiplatelet therapy? |
| Q46934452 | To adjust or not to adjust the platelet count in light transmission aggregometry in patients receiving dual aspirin/clopidogrel treatment |
| Q48182667 | Variability of on-treatment platelet reactivity in patients on clopidogrel |
| Q35691358 | Variability of platelet aggregation in patients with clopidogrel treatment and hip fracture: A retrospective case-control study on 112 patients |
Search more.